145 related articles for article (PubMed ID: 11302883)
1. Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment.
den Broeder AA; van den Hoogen FH; van de Putte LB
Ann Rheum Dis; 2001 May; 60(5):538-9. PubMed ID: 11302883
[TBL] [Abstract][Full Text] [Related]
2. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
[TBL] [Abstract][Full Text] [Related]
3. USAN Council. List No.407. New names. Lenercept.
Clin Pharmacol Ther; 1998 Aug; 64(2):234. PubMed ID: 9758530
[No Abstract] [Full Text] [Related]
4. Improved rheumatoid digital vasculitis in a patient treated with TNFalpha agent blocking (infliximab).
Benucci M; Li Gobbi F; Saviola G; Manfredi M
Rheumatol Int; 2008 Oct; 28(12):1253-5. PubMed ID: 18493770
[TBL] [Abstract][Full Text] [Related]
5. TNF-alpha-targeted therapy in rheumatoid arthritis.
Wendling D; Toussirot E
Rev Rhum Engl Ed; 1999 Apr; 66(4):187-91. PubMed ID: 10339773
[No Abstract] [Full Text] [Related]
6. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
[TBL] [Abstract][Full Text] [Related]
8. Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.
Renzetti LM; Gater PR
Inflamm Res; 1997 Aug; 46 Suppl 2():S143-4. PubMed ID: 9297552
[No Abstract] [Full Text] [Related]
9. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis.
Guignard S; Gossec L; Bandinelli F; Dougados M
Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S23-9. PubMed ID: 18799049
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Feldmann M; Maini RN
Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
[TBL] [Abstract][Full Text] [Related]
12. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
13. TNF inhibition and sepsis -- sounding a cautionary note.
Grau GE; Maennel DN
Nat Med; 1997 Nov; 3(11):1193-5. PubMed ID: 9359687
[No Abstract] [Full Text] [Related]
14. Focus on: biologics that affect therapeutic agents in dermatology.
Saripalli YV; Gaspari AA
J Drugs Dermatol; 2005; 4(2):233-45. PubMed ID: 15776786
[TBL] [Abstract][Full Text] [Related]
15. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Neurology; 1999 Aug; 53(3):457-65. PubMed ID: 10449104
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis.
Murphy CC; Greiner K; Plskova J; Duncan L; Frost A; Isaacs JD; Rebello P; Waldmann H; Hale G; Forrester JV; Dick AD
Arch Ophthalmol; 2004 Jun; 122(6):845-51. PubMed ID: 15197059
[TBL] [Abstract][Full Text] [Related]
17. Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy.
Mangat P; Whittle S; Cleland L; Limaye V
Clin Rheumatol; 2008 Dec; 27(12):1593-5. PubMed ID: 18827960
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab-associated multiple sclerosis.
Bensouda-Grimaldi L; Mulleman D; Valat JP; Autret-Leca E
J Rheumatol; 2007 Jan; 34(1):239-40; discussion 240. PubMed ID: 17216704
[No Abstract] [Full Text] [Related]
19. [Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].
Larsson P; Bratt J; Harju A; van Vollenhoven R; Klareskog L
Lakartidningen; 2001 Feb; 98(8):828-31. PubMed ID: 11265568
[TBL] [Abstract][Full Text] [Related]
20. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature.
Schett G; Herak P; Graninger W; Smolen JS; Aringer M
J Clin Microbiol; 2005 May; 43(5):2537-41. PubMed ID: 15872306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
